DFTX · NASDAQ · STOCK
Definium Therapeutics (DFTX) Stock Analysis
$36.88
52W $12.88 – $49.20
50/100
$4.90B
-10.7
2.19
Is DFTX Bullish or Bearish?
Mixed.
Innellis AI committee rates Definium Therapeutics, Inc. (DFTX) Watch with a composite score of 50/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +10.14 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -9.86 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Growth Analyst remains cautious — 4 consecutive earnings misses -- execution concerns. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.0x prices in significant intangible value — Value
- ROE of only -85.2% -- cheap may mean cheap for a reason — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 17.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
50/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 95%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.0x prices in significant intangible value
Growth Analyst
bearish
28
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock
− Bollinger bandwidth of 17.0% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 48.2 to 49.9.
- Conviction changed from contested to moderate.
- Committee agreement increased notably from 50% to 67%.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: stance bearish->neutral; score 38->48 (+10).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
50.2
Neutral
MACD Histogram
-0.084
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$19.34
Resistance
$49.16
Bollinger %B
0.40
Inside Bands
Price vs Moving Averages
EMA 9
$36.36
Above
EMA 21
$37.47
Below
EMA 50
$38.56
Below
EMA 200
$30.15
Above
Fundamental Analysis
Valuation
85
Growth
6
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-10.7×
P/B Ratio
4.45×
PEG Ratio
0.14
Dividend Yield
0.00%
52W High
$49.20
52W Low
$12.88
Quality & Growth
ROE
-5530.5%
ROA
-4176.2%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.04
AI Fundamental Assessment
P/E ratio of -10.7 (inexpensive relative to a 15-40x range); Price-to-book of 4.4x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -55.3%; Return on assets of -41.8%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 6.95 (healthy short-term liquidity); Debt-to-equity of 0.04; Free cash flow per share is negative (-1.51); Most recent quarter missed estimates by 158.2%; 4 consecutive earnings misses; EPS growth decelerating (-42.0% -> -102.8% QoQ); Analyst estimates falling over recent quarters
Get the Full DFTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →